Immunology: 5 Autoimmune Catalysts Ranked by Risk-Reward

Oncology gets the headlines and the capital. Immunology quietly built the two biggest franchises in pharma. Dupixent did $15.7 billion in 2025 sales. Skyrizi and Rinvoq combined for $8.03 billion in a single quarter. Yet investors still do not treat autoimmune disease as a sector worth tracking the way they track oncology. That is the opportunity.

The structural reason these franchises are worth more than most oncology drugs is churn. Autoimmune therapies treat chronic disease. Patients do not get cured and leave; they stay on treatment for decades. That produces recurring revenue with low attrition, which is why Dupixent can guide to €25 billion by 2030 while a checkpoint inhibitor has to win new indications every year just to hold its line. Dupixent, Skyrizi, and Rinvoq alone carry combined peak-sales guidance near $90 billion. Add Tremfya at $4 billion-plus, Benlysta at $2.4 billion, and the IL-17 field, and immunology approaches a $100 billion revenue pool built from a handful of drugs. This is the largest commercial opportunity outside oncology, and it is under-covered because there is rarely a single binary PDUFA to front-run.

Here are five catalysts, plus two more that failed or teeter, ranked by risk-reward. Prices are Polygon’s August 21 close.

1. Johnson & Johnson (JNJ): Icotyde, the First Oral IL-23

JNJ closed at $270.24 with a $644.3 billion market cap. Icotyde (icotrokinra) is the first oral drug to hit the IL-23 receptor, a pathway previously reachable only through injectable biologics. The EMA’s CHMP gave it a positive opinion on July 23, and it has been on the US market since March 18, 2026. (Icotyde CHMP coverage).

The data is what makes it matter. In the ICONIC program’s head-to-head studies against deucravacitinib, roughly 70% of patients reached clear or almost clear skin (IGA 0/1) at Week 16, and 55% hit PASI 90. Beating the current oral standard on clearance is the selling point. IL-23 inhibitors are a $4 billion-plus class, and J&J’s own injectable Tremfya does over $4 billion annually. An oral version expands the treatable pool beyond the roughly 15% of psoriasis patients currently on pills.

The verdict on Icotyde: a real drug, but immaterial to a $644 billion company. JNJ is a Hold on this catalyst alone. The stock does not trade on an oral IL-23 label; it trades on managing the Stelara patent cliff.

2. Johnson & Johnson (JNJ): Nipocalimab, First FcRn Win in Lupus

The more interesting JNJ asset is nipocalimab. The Phase 2 JASMINE trial (NCT04882878) made it the first FcRn blocker to show efficacy in lupus. At Week 52, SRI-4 response was 53.6% versus 39.7% for placebo, a 13.9 percentage point delta. In autoantibody-positive patients, the delta widened to 22.1 points. (Full JASMINE analysis).

That effect size sits between GSK’s Benlysta at 9.4 points and AstraZeneca’s Saphnelo at 16.5 points, but the FcRn mechanism is what matters. It lowers pathogenic IgG autoantibodies, the exact driver of lupus, and could open a path to a dozen autoantibody diseases. The problem is the comp. argenx’s Vyvgart already does $4.2 billion and grew 90% year over year, and argenx carries a $53 billion market cap. Nipocalimab is a Phase 2 asset chasing an entrenched leader.

For JNJ at $644 billion, nipocalimab is optionality, not a catalyst. The stock is a Hold. The pure play on FcRn is argenx, not JNJ.

3. AbbVie (ABBV): The $10.9 Billion Apogee IL-13 Bet

ABBV closed at $264.96 with a $462.7 billion market cap. The $10.9 billion Apogee Therapeutics acquisition, announced June 22, buys zumilokibart, a half-life extended IL-13 antibody with Phase 2 atopic dermatitis data and a dosing edge: maintenance every 3 to 6 months versus Dupixent’s every-2-weeks injection. (AbbVie Q2 and Apogee analysis).

The Phase 2 APEX Part B data showed EASI-75 in 65.9% of patients versus 23.4% on placebo, a 41.9% placebo-adjusted response, competitive with Lilly’s lebrikizumab (Ebglyss) at 42.6% and clearly ahead of Dupixent’s 36%. This is Phase 2, not Phase 3, and the ADventure registrational program starts in H2 2026.

The key number for valuation is 2.4%. The deal is 2.4% of AbbVie’s market cap. Skyrizi just overtook Humira at $5.5 billion in quarterly revenue and is guided to $20 billion peak. If zumilokibart fails, the write-down is absorbed. If it works, AbbVie owns the next generation of its immunology franchise. AbbVie is a Buy on the franchise, and the Apogee option comes free.

4. MoonLake (MLTX): Sonelokimab, the IL-17 Nanobody

MLTX closed at $15.76 with a $1.35 billion market cap. This is the one name on the list where the catalyst actually moves the stock. Sonelokimab is an IL-17A/F Nanobody that blocks IL-17A/A, IL-17A/F, and IL-17F/F dimers, a differentiation from Novartis’s Cosentyx (IL-17A only) and AbbVie’s Skyrizi (IL-23).

The Phase 3 IZAR-1 trial in biologic-naive psoriatic arthritis hit every endpoint: 42.1% ACR50 at Week 16, 66.5% ACR20, 41.2% Minimal Disease Activity, and 61% PASI90 in patients with skin involvement. (Sonelokimab IZAR-1 readout). The psoriatic arthritis market is worth upward of $10 billion annually. MoonLake already plans a BLA for hidradenitis suppurativa in H2 2026, giving it two shots on goal.

The risks are real: the trial is still blinded with no placebo comparison disclosed, $537 million in cash funds runway to mid-2028, and the company is pre-revenue. But at $1.35 billion market cap against two multi-billion-dollar indications, the torque is the highest in the sector. This is the speculative Buy.

5. Sanofi (SNY): Dupixent’s Growth Against a Broken Pipeline

SNY closed at $45.85 with a $108.2 billion market cap. Dupixent did €5.2 billion in Q2, up 37.6%, and Sanofi raised its 2030 target to €25 billion. But the same earnings release disclosed three immunology cuts, itpekimab, balinatunfib, and amlitelimab, with combined write-offs above €1 billion. The stock fell 5.8% on a beat-and-raise quarter. (SNY Q2 pipeline cuts analysis).

The risk is the 2031 patent cliff. Dupixent’s US composition-of-matter patent expires October 2027 with an extension to March 2031. Sanofi trades at 1.9x sales versus AbbVie at 7.23x, and the discount is earned: the market does not believe the pipeline can replace Dupixent before biosimilars arrive. Sanofi is a Hold until a deal or a Phase 3 initiation provides evidence the R&D engine can produce a successor.

Two More That Failed or Teeter

Celldex (CLDX) closed at $40.38 with a $3.14 billion market cap. Barzolvolimab failed its Phase 2 in prurigo nodularis, missing the itch endpoint with p=0.868 on the 150mg dose despite profound mast cell depletion. (Barzolvolimab failure). The entire thesis now rests on the chronic spontaneous urticaria Phase 3 readout in September or October. That is a coin flip, and the stock is priced as if the coin lands heads. Avoid ahead of a binary you cannot predict.

Kiniksa (KNSA) closed at $79.03 with roughly a $6.1 billion market cap. KPL-387 is a monthly IL-1 shot designed to replace Kiniksa’s own weekly Arcalyst, which did $243.6 million in Q2 and is guided to nearly $1 billion for 2026. Arcalyst won its approval on the RHAPSODY trial, which showed a 96% reduction in recurrence risk (NEJM). (KPL-387 monthly IL-1 setup). The problem is self-cannibalization: KPL-387 does not open a new market, it defends the existing one. At 7x sales the stock prices in a perfect transition. Hold, and buy the reaction to the Phase 2 data, not the anticipation.

Risks

The sector-wide risk is Phase 2 to Phase 3 failure. Lupus, atopic dermatitis, and psoriatic arthritis all have brutal histories of Phase 2 data not replicating. Nipocalimab’s 6.8 point Week 24 delta is thin. Sonelokimab has no placebo-controlled psoriatic arthritis data yet. Zumilokibart is still pre-Phase 3. Every catalyst on this list except Icotyde carries binary clinical risk.

The commercial risk is concentration. Dupixent is 45% of Sanofi’s net sales. Skyrizi and Rinvoq are AbbVie’s growth engine. If a biosimilar or a better-dosed competitor arrives early, the franchise math changes fast. The recurring-revenue advantage that makes immunology valuable also makes it a target.

The Ranking

1. MLTX sonelokimab: highest torque, two multi-billion-dollar indications, but pre-revenue and binary. Speculative Buy.
2. ABBV Apogee: asymmetric risk at 2.4% of market cap, and the franchise already prints cash. Buy.
3. KNSA KPL-387: revenue base protects the downside, but the upside is capped by self-cannibalization. Hold.
4. JNJ nipocalimab and Icotyde: real drugs, immaterial to a $644 billion stock. Hold.
5. SNY Dupixent: cheap, but the pipeline credibility gap is earned. Hold.
6. CLDX barzolvolimab: a coin-flip urticaria readout priced for success. Avoid.

The takeaway: immunology rewards two things, the pure play with the highest torque (MLTX) and the mega-cap with the asymmetric option (ABBV). Everyone in the middle is either too big for the catalyst to matter or too binary to predict. If you want autoimmune exposure, buy the specialist with two shots on goal or the franchise with a free pipeline option. Skip the giants and the coin flips.